Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 12, 2004, Pages 4597-4605

  Sprandel, Kelly A ^a   Schriever, Christopher A ^a   Pendland, Susan L ^a   Quinn, John P ^c   Gotfried, Mark H ^a,d,e   Hackett, Suzanne ^f   Graham, Mary Beth ^g   Danziger, Larry H ^a,b   Rodvold, Keith A ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e Pulmonary Associates   (United States)

^f StatWorks Inc   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; METRONIDAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; BACTEROIDES THETAIOTAOMICRON; BLOOD SAMPLING; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG SCREENING; ESCHERICHIA COLI; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NONHUMAN; NORMAL HUMAN; PEPTOSTREPTOCOCCUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STEADY STATE; URINALYSIS;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIA, ANAEROBIC; BACTEROIDES; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ESCHERICHIA COLI; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OFLOXACIN; PEPTOSTREPTOCOCCUS;

EID: 9644303233     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.12.4597-4605.2004     Document Type: Article

References (34)

1. Anonymous. 1996. Metronidazole injection, USP RTU prescribing information. Baxter Healthcare Corporation, Deerfield, Ill.
2. Anonymous. 2004. Levaquin prescribing information. Ortho-McNeil Pharmaceutical, Inc., Raritan, N.J.
3. Auger, P., J. Bourgouin, and C. Bagot. 1988. Intravenous metronidazole in the treatment of abdominal sepsis: once vs three times daily administration. Curr. Ther. Res. 43:494-502.
4. Bergan, T., S. Aase, O. Leinebo, M. Roland, T. Harbitz, A. Olsen, and I. Liavag. 1984. Pharmacokinetics of metronidazole and its major metabolite after a high intravenous dose. Scand. J. Gastroenterol. 19(Suppl. 91):113-123.
5. Bergan, T., J. H. Solhaug, O. Soreide, and O. Leinebo. 1985. Comparative pharmacokinetics of metronidazole and tinidazole and their tissue penetration. Scand. J. Gastroenterol. 20:945-950.
6. Chow, A. T., C. Fowler, R. R. Williams, N. Morgan, S. Kaminski, and J. Natarajan. 2001. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 45:2122-2125.
7. Craig, W. A., and S. C. Ebert. 1991. Killing and regrowth of bacteria in vitro: a review. Scand. J. Infect. Dis. 74(Suppl.):S63-S70.
8. Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 296-329. In V. L. Lorian (ed.), Antibiotics in laboratory medicine, 4th edition. Williams & Wilkins, Baltimore, Md.
9. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
10. Du Bois, D., and E. F. Du Bois. 1989. A formula to estimate the approximate surface area if height and weight be known. [1916.] Nutrition 5:303-311.
11. Finegold, S. M. 2000. Metronidazole, p. 361-366. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 5th ed., vol. 1. Churchill Livingstone, Philadelphia, Pa.
12. Granneman, G. R., and L. L., Varga. 1991. High-performance liquid chromatographic procedures for the determination of temafloxacin in biological matrices. J. Chromatogr. 568:197-206.
13. Haller, I. 1982. In vitro activity of the two principal oxidative metabolites of metronidazole against Bacteroides fragilis and related species. Antimicrob. Agents Chemother. 22:165-166.
14. Jensen, J. C., and R. Gugler. 1983. Sensitive high-performance liquid chromatographic method for the determination of metronidazole and metabolites. J. Chromatogr. 277:381-384.
15. Lau, A. H., K. Emmons, and R. Seligsohn. 1991. Pharmacokinetics of intravenous metronidazole at different dosages in healthy subjects. Int. J. Clin. Pharmacol. Ther. Toxicol. 29:386-390.
16. Lewis, R. E., M. E. Klepser, E. J. Ernst, M. A. Snabes, and R. N. Jones. 2000. Comparison of oral immediate-release (IR) and extended-release (ER) metronidazole bactericidal activity against Bacteroides spp. using an in vitro model of infection. Diagn. Microbiol. Infect. Dis. 37:51-55.
17. Loft, S., M. Dossing, H. E. Poulsen, J. Sonne, K. L. Olesen, K. Simonsen, and P. B. Andreasen. 1986. Influence of dose and route of administration on disposition of metronidazole and its major metabolites. Eur. J. Clin. Pharmacol. 30:467-473.
18. Luke, M., J. J. Iversen, J. Sondergaard, E. Kvist, P. Lund, F. Anderson, L. Naver, P. Norgaard Larsen, B. Clausen, and J. Prag. 1991. Ceftriaxone/metronidazole is more effective than ampicillin/netilmicin/ metronidazole in the treatment of bacterial peritonitis. Eur. J. Surg. 157:397-401.
19. Martin, C., B. Sastre, M. N. Mallet, B. Bruguerolle, J. P. Brun, P. De Micco, and F. Gouin. 1991. Pharmacokinetics and tissue penetration of a single 1,000-milligram, intravenous dose of metronidazole for antibiotic prophylaxis of colorectal surgery. Antimicrob. Agents Chemother. 35:2602-2605.
20. Mazuski, J. E., R. G. Sawyer, A. B. Nathens, J. T. DiPiro, M. Schein, K. A. Kudsk, and C. Yowler. 2002. The surgical infection society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg. Infect. 3:161-173.
21. Metropolitan Life Insurance Company. 1983. Metropolitan height and weight tables. Stat. Bull. 64:2-9.
22. National Committee for Clinical Laboratory Standards. 1999. Methodology for the serum bactericidal test; approved guideline. NCCLS document M21-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
23. National Committee for Clinical Laboratory Standards. 2001. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, 5th ed. NCCLS document M11-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. Nix, D. E., R. Tyrell, and M. Muller. 1995. Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis. Antimicrob. Agents Chemother. 39:1848-1852.
25. Ohlin, B., A. Cederberg, H. Forssell, J. Helge Solhaug, and E. Tveit. 1999. Piperacillin/tazobactam compared with cefuroxime/metronidazole in the treatment of intra-abdominal infections. Eur. J. Surg. 165:875-884.
26. O'Keefe, J. P., K. A. Troc, and K. D. Thompson. 1982. Activity of metronidazole and its hydroxy and acid metabolites against clinical isolates of anaerobic bacteria. Antimicrob. Agents Chemother. 22:426-430.
27. Pendland, S. L., S. C. Piscitelli, P. C. Schreckenburger, and L. H. Danziger. 1994. In vitro activity of metronidazole and its hydroxy metabolite against Bacteroides spp. Antimicrob. Agents Chemother. 38:2106-2110.
28. Rabin, H. R., R. C. Urtasun, J. Partington, D. Koziol, M. Sharon, and K. Walker. 1980. High-dose metronidazole: pharmacokinetics and bioavailability using an IV preparation and application of its use as a radiosensitizer. Cancer Treat. Rep. 64:1087-1095.
29. Ralph, E. D. 1983. Clinical pharmacokinetics of metronidazole. Clin. Pharmacokinet. 8:43-62.
30. Selkon, J. B. 1981. The need for and choice of chemotherapy for anaerobic infections. Scand. J. Infect. Dis. 26:19-23.
31. Smith, A. J., T. Daniels, and J. M. A. Bohnen. 1996. Soft tissue infections and the diabetic foot. Am. J. Surg. 172(Suppl. 6A):7S-12S.
32. Solhaug, J. H., T. Bergan. O. Leinebo, A. R. Rosseland, L. Spada, and F. Vaagenes. 1984. The pharmacokinetics of one single preoperative dose of metronidazole or tinidazole. Scand. J. Gastroenterol. 19(Suppl. 90):89-96.
33. Solomkin, J. S., J. E. Mazuski, E. J. Baron, R. G. Sawyer, A. B. Nathens, J. T. DiPiro, T. Buchman, E. P. Dellinger, J. Jemigan, S. Gorbach, A. W. Chow, and J. Bartlett. 2003. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin. Infect. Dis. 37:997-1005.
34. Soreide, O., O. Leinebo, T. Bergan, K. Bakkevold, B. Salvesen, and N. M. Ulvik. 1984. Comparative pharmacokinetics of metronidazole and tinidazole used as single dose prophylactic agents. Scand. J. Gastroenterol. 19(Suppl. 90):97-106.